We would love to hear your thoughts about our site and services, please take our survey here.
Viatris will be watching in glee, but I am shocked by this update - the board is incompetent
This is what we should be celebrating:
“The prescriptions in Q3 2023 are on track to exceed the total for the entire first six months of the year. Excellent initial results following the commercial expansion put Shield on track to reach a major corporate milestone for 2023, with line of sight to total Accrufer® prescriptions of 100,000 to 130,000. Since the completion of the sales force expansion in May, Accrufer® has grown an average of 26% month over month through to the end of August.”
Why would it be a distressed sale? The product is solid and the intake is slower than expected - positive cash flows would come in time. And the board would want to maximise shareholder value as much as possible - and there would be many interested parties for an fda approved drug which is a wonder drug in the iron deficiency sector.
This is an easy buy into a cash generative product and would be a no brainer for £12bn MCAP Viatris.
Sales could be lower than predicted and still generate cash to be self sufficient.
Which would mean it’s time to sell up - And then the board and institutional shareholders deciding that it’s better suited for a sale. Viatris would be first in
Luckily STX's deal with Viatris gives us a massive safety net in case sales are slower than expected.
Although I am expecting big things from Accrufer in the US and sales exponentially rising. On the off chance that sales are slower and not hitting the dizzying heights - then i fully expect Viatris (a Pharma with some great products in its portfolio) to add Accrufer as a way of having consistent cash generation.. For me, its a win win situation.. DYOR.
News next week and expecting this to do well. Hopefully positive set of prescription data with healthy growth figures.
Can’t wait!
Good investor presentation re-iterating some important milestones to come. News flow in the future will include many positives and they made it pretty clear that they are there to add some serious value here.
Holding long term and looking forward to updates as they come.
Although I am a holder at a high average I’m reading between the lines of the hardman research and you’ll see that the share capital increases significantly which possibly shows that they’re already in the know about an equity raise.
Unfortunately, more value lost.
The messaging from the board is that discussions are in place and there is confidence that there will be some sort of facility in place for it.
A real positive HY result and positive statements from the CEO about the future of the company.
4x growth in sales - and more to come.
There isn’t real positive sentiment here. We have a new CEO who we haven’t really heard much from and was expecting him to ramp up the PR instead of churning old information which we already know.
This will take several months to get some form of meaningful data from the US.
Also selling costs have increased(note 5), with peanuts income
Just a disappointing RNS when it came to providing highlights - Needed to present numbers of reps we have, and data on how they’re getting on with selling in the US.
Cashflow isn’t an issue… yet - but 8m spent on what so far??
Why present to an investor forum if the company is struggling for cash???
What are they trying to achieve? Except maybe and other fundraise
Target hit. But I suspect it may drop further. Waiting and seeing.
Where’s that guy that called me an idiot? Hahaha
...why?
1 - Now has enough working capital to get it to a point where it will in positive EBITDA territory and positive operating cash flow generation through its rolayty programme.
2 - US Launch is going to add lots of value, alongside exisiting deals which give it its foundations
3 - Underpinned by solid IP
4 - Large addressable market needs.
For me, a no brainer, and for those who came in earlier at £1+ - be patient.... this will come good.
Dont worry i'll soon start ramping once it hits 17p
Its dropping :)
Thats why i said TARGET you idiot - give it an hour.
Expecting all profit takers to sell now given the quick drop - buy price is 17p now.
Totally agree. With a ridiculous MCAP of around £30m - this should easily be a £100m+ company,